Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Common Equity (2016 - 2020)

Trinity Biotech (TRIB) has disclosed Common Equity for 5 consecutive years, with -$2.2 million as the latest value for Q4 2020.

  • Quarterly Common Equity fell 147.08% to -$2.2 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was -$2.2 million through Dec 2020, down 147.08% year-over-year, with the annual reading at -$2.2 million for FY2020, 147.08% down from the prior year.
  • Common Equity hit -$2.2 million in Q4 2020 for Trinity Biotech, down from $4.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $108.7 million in Q4 2016 to a low of -$2.2 million in Q4 2020.
  • Historically, Common Equity has averaged $44.1 million across 5 years, with a median of $44.1 million in 2018.
  • Biggest five-year swings in Common Equity: tumbled 32.43% in 2018 and later plummeted 147.08% in 2020.
  • Year by year, Common Equity stood at $108.7 million in 2016, then plummeted by 40.04% to $65.2 million in 2017, then crashed by 32.43% to $44.1 million in 2018, then plummeted by 89.3% to $4.7 million in 2019, then tumbled by 147.08% to -$2.2 million in 2020.
  • Business Quant data shows Common Equity for TRIB at -$2.2 million in Q4 2020, $4.7 million in Q4 2019, and $44.1 million in Q4 2018.